Defining the Genetic and Phenotypic Landscape of Primary Immune Regulatory Disorders Using the ClinGen Validation Framework
Solomon, B. D., Ross, J., Fensterle, E. P., Soliman, R. S., Paczosa, M. K., Brittain, A., Forbes, E. M., Sarmento, O. F., et al.
allergy and immunology
Quick verdict
ClinGen panel curates 49 PIRD gene-disease pairs (28 definitive) and 3 HPO phenotype clusters; rigorous, clinically useful, with minor inconsistencies.
Summary
This preprint reports the first systematic ClinGen-framework validation of gene-disease relationships for primary immune regulatory disorders (PIRDs). Between July 2023 and April 2026, the PIRD Gene Curation Expert Panel curated 46 genes and 49 relationships drawn from IUIS Table 4 and expert nomination, applying the semiquantitative ClinGen SOP (genetic evidence up to 12 points; experimental up to 6). Of 49 relationships, 28 were classified definitive, 2 strong, 9 moderate, 7 limited, and 3 disputed; inheritance is predominantly autosomal recessive (35/49). The panel also harmonized disease nomenclature across MONDO, OMIM, and IUIS with a dyadic [gene]-related immune disorder scheme. From 2,131 HPO annotations on over 340 curated patients, the authors built GIC-similarity networks and applied Leiden clustering, identifying three phenotypic modules: atopic/GI inflammation; immune deficiency with autoimmunity; and lymphoproliferation with systemic inflammation. The clusters broadly track IUIS subtables and correctly separate the three mechanistically distinct STAT1 entities, providing internal validation. Limitations include a GDR classified definitive (TPP2, 11.70/18) below the depicted 12-point threshold; disputed labels on near-zero-evidence GDRs; absence of quantitative cluster-stability statistics; curations capped once definitive classification is reached, limiting score comparability; and no visible code availability. Overall a rigorous, clinically consequential curation resource whose tables will inform variant interpretation, while the phenotypic clustering claims need formal validation and deposited code.
Review complete
Assessment at a glance
5
risk flags identified
● high 0
● medium 3
● low 2
5 strengths · 5 weaknesses · 5 author questions
AI text signal = Binoculars zero-shot detector score over 20 sampled passages (Fast-DetectGPT co-reported) — absence does not prove human authorship, and a flag does not imply misconduct.
Levels reflect verification complexity — not a quality score. Evolve never rates your paper.
Key claims under review
- As of April 2026, the ClinGen PIRD-GCEP curated 46 genes and 49 gene-disease relationships, classifying 28 as definitive, 2 strong, 9 moderate, 7 limited, and 3 disputed.
- Unsupervised clustering of 2,131 HPO annotations resolves PIRDs into three conserved phenotypic modules: atopic/GI inflammation, immune deficiency with autoimmunity, and lymphoproliferation with systemic inflammation.
- The phenotypic modules broadly align with IUIS subtables yet transcend them, and correctly separate the mechanistically distinct STAT1 LOF, dominant-negative, and gain-of-function entities.
- A harmonized dyadic nomenclature ([gene]-related immune disorder) resolves cross-database naming conflicts among MONDO, OMIM, and IUIS.
- These validated classifications constitute a resource that directly supports clinical variant interpretation and may reduce diagnostic delay in PIRDs.
Strengths
Standardized, transparent evidence framework applied at scale
49 GDRs scored under ClinGen SOP v8-12 with per-GDR genetic/experimental point totals in Table 2 (e.g., UNC13D 12+6, CASP10 1.30+3.50), an auditability narrative reviews cannot offer; curations live in the public Gene Curation Interface.
Framework discipline against over-interpreting experimental data
PDCD1 held at limited (2/12 genetic) despite a maximal 6/6 experimental score; CASP10 downgraded on allele frequencies >0.05 and confounding apoptosis-pathway variants — biological plausibility cannot override scarce genetics.
Phenotype standardization with explicit annotation-bias mitigation
Practical clinical outputs
Honest reporting of null comparisons
Weaknesses
Internal threshold inconsistencies in Table 2
Disputed taxonomy applied to evidence-poor GDRs
No quantitative validation of the three-cluster claim
Scores not comparable across GDRs due to curation capping
Data-hygiene and reporting gaps
Full Review Report
$1.99 · one-timeUnlock the complete preliminary analysis Evolve produced for this paper.
Report preview
Scope & Claims
This medRxiv preprint (posted 2026-09-17; not certified by peer review) reports the ClinGen PIRD Gene Curation Expert Panel's systematic validity assessment of gene-disease relationships (GDRs) for primary immune regulatory disorders. Scope came from IUIS IEI Table 4 (2022/2024) plus expert nomination: 51 genes from the 2022 table, of which 46 were not assigned to other immunology GCEPs; 18 added from the 2024 update; 23 from domain expertise. Of this scope, 46 genes/49 GDRs were curated by April 2026 (42 more genes pending, Supplemental Table 3). Four claims are made: (1) a validated classification set — 28 definitive, 2 strong, 9 moderate, 7 limited, 3 disputed (Table 2); (2) three HPO-derived phenotypic clusters transcending IUIS tables; (3) harmonized dyadic nomenclature; (4) clinical utility for variant interpretation and diagnosis. Claims 1 and 3 are well supported by the displayed evidence; claim 2 is plausible but formally under-validated; claim 4 is an extrapolation — no diagnostic-yield or variant-lab impact data are presented.
The remaining sections cover Methodology Assessment, Statistical Evidence, Results & Reproducibility, Limitations & Risks, and Verdict & Recommendations.
- All 5 strengths & 5 weaknesses, analyzed in detail
- 5 risk flags with severity, section & reviewer questions
- Methods & statistical evidence assessment
- 5 questions a peer reviewer would ask
- Full six-dimension evaluation report & recommendations
One-time purchase · this paper only
One-time purchase, this paper only. AI-generated preliminary analysis — not peer review.
Frequently asked questions
What are primary immune regulatory disorders (PIRDs)?
PIRDs are a group of inherited immune disorders in which the immune system is dysregulated rather than simply absent — causing autoimmunity, chronic inflammation, lymphoproliferation (enlarged lymph nodes and spleen), atopy/allergy, and sometimes infection susceptibility.
How many PIRD gene-disease relationships were validated and how strong is the evidence?
As of April 2026 the ClinGen PIRD expert panel curated 49 relationships across 46 genes: 28 definitive, 2 strong, 9 moderate, 7 limited, and 3 disputed, using ClinGen's point-based framework (up to 12 points of genetic plus 6 points of experimental evidence).
What are the three phenotypic clusters of PIRDs identified in this study?
Using HPO-based network clustering, the authors identified: (1) atopic and gastrointestinal inflammation (dermatitis, diarrhea, colitis); (2) immune deficiency with classic autoimmunity (recurrent infections, bronchiectasis, lupus, autoantibodies); and (3) lymphoproliferation with systemic inflammation (lymphadenopathy, hepatosplenomegaly, cytopenias, fevers).
What does a definitive ClinGen classification mean?
It is ClinGen's highest gene-disease validity level: the combined evidence reaches the strong category (12-18 points) and replicated genetic cases have been reported over at least three years, so the relationship is considered established for clinical variant interpretation.
About this review
This is an AI-generated preliminary review by Evolve.Pub, produced from the openly available text of the paper. It is not peer review and does not represent the authors' views. The canonical record of the paper is at the publisher link above.
- Two passages were omitted in text extraction (parts of the methods on the statistical pipeline and parts of the discussion); UMAP/Leiden parameters and a possible data/code availability statement may reside in the omitted text.
- Figures are available only as extracted text dumps (axis labels, node lists); the clustering figures could not be visually assessed.
- This is an uncertified medRxiv preprint; ClinGen classifications are periodically updated at clinicalgenome.org and may have moved since April 2026.
- Supplemental Table 3 and portions of the supplemental references were only partially extracted.
Go deeper on this paper
Wrote a paper? Stress-test it before reviewers do.
Upload your manuscript for the same structured scrutiny — reasoning, statistics, evidence, figures, and reproducibility.